表没食子儿茶素没食子酸酯对大鼠胰岛素抵抗的影响

目的研究表没食子儿茶素没食子酸酯（EGCG）对自发性2型糖尿病GK大鼠的胰岛素抵抗的影响及作用机制。方法 自发性2型糖尿病GK大鼠40只,同系健康对照Wistar大鼠10只,大鼠随机分为：正常对照组、2型糖尿病对照组、2型糖尿病低剂量EGCG（50 mg/kg）治疗组、中剂量（100 mg/kg）组、高剂量EGCG（300 mg/kg）组。干预6周后,分别检测葡萄糖耐量试验、胰岛素耐受试验、肝脏GcK、G6P以及PEPCKmRNA表达情况,以及骨骼肌细胞膜GLUT4含量的变化。结果各剂量治疗组的糖耐量均得到明显改善（P〈0.05）,胰岛素耐量在240 min时较模型对照组有明显差异（P〈0.05）。与模型组比较,低剂量和中剂量治疗组均能提高肝脏葡萄糖激酶（GcK）mRNA的表达（P〈0.05）,同时抑制葡萄糖-6-磷酸酶（G6P）和磷酸烯醇式丙酮酸激酶（PEPCK）mRNA的表达（P〈0.05）;高剂量治疗组肝脏三类酶mRNA的表达与模型对照组相比无明显差异。各剂量治疗组GK大鼠的骨骼肌细胞膜GLUT4的含量较模型对照组均具有明显上调（P〈0.05）。结论中低剂量EGCG可以改善GK大鼠胰岛素抵抗,其作用机制可能与抑制肝脏糖异生作用以及骨骼肌GLUT4的转位水平有关,并且EGCG具有代偿胰岛素的作用。     

槟榔碱对2型糖尿病大鼠肝脏胰岛素抵抗的作用

目的：探讨槟榔碱对2型糖尿病大鼠肝脏胰岛素抵抗的影响及其机制。方法：采用高果糖饲料饲养Wistar大鼠12周制备2型糖尿病大鼠模型,实验动物随机分为5组（n=8）：对照组、模型组、模型＋不同浓度的槟榔碱（0,0．5,1,5mg／kg）组。4周后通过检测血糖、血脂、胰岛素、RT-PCR检测肝脏组成型雄甾烷受体（CAR）、孕甾烷x受体（PXR）、糖代谢相关基因：葡萄糖-6-磷酸酶（G6Pase）、磷酸烯醇式丙酮酸羧激酶（PEPCK）和炎症相关因子：白细胞介素-6（IL-6）、肿瘤坏死因子α（TNF-α）mRNA表达,Western blot检测大鼠肝内p-AKT和葡萄糖转运体4（GLUT4）蛋白表达。结果：1,5mg／kg槟榔碱显著降低糖尿病大鼠体重、空腹血糖、空腹胰岛素、血脂和糖代谢相关基因及炎症相关因子mRNA水平,提高CAR、PXR mRNA水平及p-AKT、GLUT4蛋白水平。结论：槟榔碱可能通过提高CAR和PXR的表达,导致肝脏糖代谢关键酶PEPCK、G6Pase基因表达或者炎性因子肿瘤坏死因子-α（TNF-α）、白介素-6（n-6）表达降低,改善2型糖尿病大鼠肝脏胰岛素抵抗。     

十二指肠-空肠转流手术对2型糖尿病大鼠胰岛素抵抗的改善作用

目的建立十二指肠-空肠转流手术(duodenal-jejunal bypass surgery,DJB)动物模型,观察术后GK大鼠胰岛素抵抗情况的变化,研究DJB手术治疗2型糖尿病的机理。方法雄性Wistar大鼠为空白对照组;雄性GK大鼠分为模型对照组和DJB手术组。分别于手术后3、6和9周每组随机抽取6只动物进行高胰岛素-正葡萄糖钳夹实验;钳夹实验结束后1周,检测肝脏Gc K、G6P以及PEPCK mRNA表达情况以及骨骼肌细胞膜GLUT4含量变化。结果术后3周和6周,DJB手术组动物的葡萄糖输注率(GIR)较模型对照组差异无显著性(P0.05),肝脏Gc K、G6P以及PEPCK mRNA表达量较模型对照组差异无显著性(P0.05);术后9周,DJB手术组动物的葡萄糖输注率(GIR)显著高于模型对照组(P0.05),肝脏Gc K表达量DJB手术组显著高于模型对照组(P0.05),而G6P以及PEPCK mRNA表达量显著低于模型对照组(P0.05);DJB手术后3、6和9周,DJB手术组骨骼肌细胞膜GLUT4的含量较模型对照组差异无显著性(P0.05)。结论 DJB手术改善血糖的水平是通过改善体内肝脏组织的胰岛素抵抗,通过调节糖代谢酶的表达,进而提高肝脏葡萄糖摄取并抑制肝脏糖异生作用。在实验周期内,DJB手术对于骨骼肌组织的胰岛素抵抗未发现有明显改善,提示DJB手术治疗2型糖尿病的效果与时间有一定关系。     

葡萄糖激酶激活剂研究进展

葡萄糖激酶分布在体内多个脏器中,可感应葡萄糖和调节糖代谢激素,在稳定血糖水平方面起到重要作用。葡萄糖激酶激活剂系 针对这一靶点而开发,能够通过葡萄糖浓度刺激的胰岛素分泌、降低胰高血糖素浓度和肝糖输出、促进肝糖原合成以及调控肠促胰素释 放等机制来稳定体内血糖水平,近年来已成为2 型糖尿病新型药物研发的热点。介绍现有葡萄糖激酶激活剂药物的开发策略、作用特点 及临床研究进展。     

小分子葡萄糖激酶激动剂

2 型糖尿病作为一种慢性代谢疾病,目前尚无理想的治疗药物。葡萄糖激酶能够迅速将葡萄糖磷酸化,在降低促使胰岛β 细胞释放胰岛素的葡萄糖调定点、调控肝葡萄糖代谢这2 个方面发挥着重要作用。小分子葡萄糖激酶激动剂因在降血糖方面的作用而有望成为新一代治疗2 型糖尿病的药物。以葡萄糖激酶为靶点的小分子化合物陆续进入临床试验阶段,但尚无相关药物获准上市。对近几年报道的小分子葡萄糖激酶激动剂进行综述。     

AdipoRon对2型糖尿病小鼠的治疗及其可能的肝脏机制

目的：观察口服脂联素受体激动剂（AdipoRon）对2型糖尿病小鼠的治疗效果及对肝脏的影响。方法：40只SPF级雄性C57/BL6小鼠随机分为正常对照组和实验组,实验组给予高糖高脂饲养联合腹腔注射小剂量链脲佐菌素建立二型糖尿病（T2DM）小鼠模型,随机分为模型对照（DM）组,低剂量AdipoRon治疗（DM+L）组,高剂量AdipoRon治疗（DM+H）组（n=10）。检测血清中丙氨酸转氨酶（ALT）、天门冬氨酸转氨酶（AST）、碱性磷酸酶（ALP）的变化;HE染色镜下观察肝细胞形态学变化;实时定量荧光PCR法检测肝脏中肝糖类相关基因（PEPCK）的表达。结果：与DM组小鼠比较,DM+H组和DM+L组小鼠ALT、AST、ALP、甘油三酯（TG）、葡萄糖（GLU）水平均降低（P<0.05）;与DM组小鼠比较,DM+H组小鼠和DM+L组小鼠血清游离脂肪酸（FFA）浓度显著下降（P<0.05）,而肝组织葡萄糖-6-磷酸酶（G-6-P）活性DM+L组小鼠显著下降,DM+H组小鼠无显著差异;与DM组小鼠比较,DM+H组小鼠肝组织磷酸烯醇式丙酮酸羧激酶（PEPCK） mRNA表达显著降低（P<0.05）,而DM+L组小鼠无显著差异。结论：给予AdipoRon治疗的小鼠血糖降低,ALT、AST、ALP的水平及G-6-P和PEPCK的表达下降,表明AdipoRon对2型糖尿病具有显著的治疗效果,对糖尿病小鼠肝脏有一定的保护作用。     

微小核糖核酸106b对肝细胞葡萄糖异生的影响及机制*

目的: 探讨微小核糖核酸106b(miR-106b)对肝细胞葡萄糖异生作用及其机制。方法: 正常人L02肝细胞培养于含10%胎牛血清的DMEM中,利用miR-106b模拟物和抑制剂(mimics和antagomiR,分别20 nmol/L)处理L02肝细胞24 h,Western blot法检测蛋白和磷酸化蛋白的表达,定量RT-PCR检测mRNA的表达,葡萄糖试剂盒检测培养液中葡萄糖含量。结果: miR-106b模拟物可明显增加磷酸烯醇式丙酮酸羧激酶(PEPCK)和葡萄糖-6-磷酸酶(G6Pase)的蛋白表达(P均＜0.01)、增加磷酸烯醇式丙酮酸羧激酶1(PCK1)的mRNA表达(P＜0.01)、降低葡萄糖激酶(GCK)的mRNA表达(P＜0.01)。miR-106b抑制剂可显著降低PEPCK和G6Pase的蛋白表达(P均＜0.01)、降低PCK1的mRNA表达(P＜0.01)、增加GCK的mRNA表达(P＜0.01)。此外,miR-106b模拟物或抑制剂可显著降低或增加信号转导和转录激活子3(STAT3)的蛋白表达(P均＜0.01)。STAT3特异性抑制剂可显著拮抗miR-106b抑制剂对肝细胞葡萄糖异生的抑制作用。结论: miR-106b通过抑制STAT3信号通路而增加肝细胞葡萄糖异生。     

小檗碱对2型糖尿病ICR小鼠模型的治疗作用

目的比较小檗碱及小檗碱与添加剂对2型糖尿病ICR小鼠模型的降糖、降脂效果。方法100只三周龄雄性ICR小鼠随机分为正常组、模型组、小檗碱组、小檗碱加低剂量添加剂组、小檗碱加高剂量添加剂组及二甲双胍组,以高糖高脂加尿链佐菌素诱导小鼠2型糖尿病模型,并分别以小檗碱、小檗碱加低剂量添加剂、小檗碱加高剂量每天灌胃干预治疗6周。检测血糖、血清血脂、肾功指标的变化情况;给药前后做糖耐量胰岛素耐量实验。每周量小鼠体重,动态观察小鼠体重变化。代谢笼中测量小鼠饮食水量变化。结果模型组血糖较普食组显著上升（P〈0.01）,且维持较好;血脂指标CHO、HDL-c、LDL-c均较普食组升高（P〈0.05）;其他各检测生化指标差异不显著。小檗碱组空腹血糖较模型组总体下降趋势明显且维持较好（P〈0.01）;血脂较模型组有降低;糖耐量胰岛素耐量较模型组有改善。二甲双胍组血糖较模型组有下降趋势,血脂较模型组无显著差别。小檗碱加低剂量添加剂组较模型组血糖血脂无显著差别。小檗碱加高剂量添加剂组血糖较模型有下降趋势,血脂较模型组有下降趋势,其他各项生化指标均无差别。结论小檗碱降糖效果优于二甲双胍,小檗碱加低剂量添加剂,小檗碱加高添加剂。     

基于己糖激酶与葡萄糖-6-磷酸脱氢酶共表达的辅酶NADPH高效再生

【目的】构建己糖激酶与葡萄糖-6-磷酸脱氢酶的大肠杆菌共表达体系,以葡萄糖为底物实现辅酶NADPH的高效再生。【方法】通过分子生物学方法,克隆己糖激酶HKgs、HKpp基因,并于Escherichia coli BL21(DE3)中表达,再将己糖激酶HKgs、HKpp分别与葡萄糖-6-磷酸脱氢酶Gpd PP共表达,实现NADPH的原位再生。比较两个共表达工程菌的辅酶再生效果,并针对催化活力较高的工程菌BL21(HKgs+Gpd PP)进行表达条件优化。【结果】NADPH再生活力达到856 U/L。该辅酶再生体系与醇脱氢酶Adh R联合催化,使不对称还原4-氯乙酰乙酸乙酯的催化活力提高至原始值的2.5倍。【结论】通过己糖激酶与葡萄糖-6-磷酸脱氢酶在大肠杆菌中的共表达,构建了一个新的NADPH高效再生体系,并用于醇脱氢酶催化的不对称还原反应。     

尾加压素Ⅱ抑制葡萄糖激酶的表达和葡萄糖诱导的胰岛素分泌

本研究旨在探讨尾加压素II(urotensin II,UII)对胰岛β细胞功能的影响及其机制。在整体实验中,采用Wistar大鼠进行糖耐量试验,检测不同剂量UII(3、30、300nmol/kg)对大鼠血糖和胰岛素水平的影响;在细胞实验中,βTC-6细胞孵育实验检测UII对葡萄糖引起的胰岛素分泌(glucose-induced insulin secretion,GIIS)的影响,酸化乙醇抽提法和实时荧光定量PCR分别测定细胞内胰岛素含量和mRNA的水平,Western blot检测胰十二指肠同源盒1(pancreatic duodenal homeobox-1,PDX-1)和葡萄糖激酶(glucokinase,GCK)表达水平。糖耐量试验结果显示,相对对照组,急性静脉注射较高剂量的UII(30、300nmol/kg)使大鼠血浆胰岛素浓度在腹腔注射葡萄糖后15min显著下降,并且使大鼠血糖在腹腔注射葡萄糖后90min明显升高。βTC-6细胞孵育实验结果显示,UII孵育2h能抑制βTC-6细胞的GIIS,但是对细胞内的胰岛素含量和mRNA水平没有影响。UII对GIIS的抑制作用可以被UII受体拮抗剂urantide所阻断,部分被蛋白激酶C(protein kinase C,PKC)非特异性抑制剂chelerythrine chloride(CTC)和生长抑素受体非特异性拮抗剂cyclosomatostatin(CSS)所阻断。Western blot结果显示,UII抑制了βTC-6细胞内GCK的表达,但对PDX-1表达量没有影响。以上结果表明,UII通过激活其特异性受体(较高浓度的UII可能同时激活生长抑素受体)抑制胰岛β细胞GIIS,其作用机制涉及PKC通路的激活、GCK表达受抑所引起的胰岛素颗粒胞吐作用的减弱,但不涉及胰岛素本身表达的下降。     

Sodium arsenite induces orphan nuclear receptor SHP gene expression via AMP-activated protein kinase to inhibit gluconeogenic enzyme gene expression

Sodium arsenite has been demonstrated to alter the expression of genes associated with glucose homeostasis in tissues involved in the pathogenesis of type 2 diabetes; however, the underlying molecular mechanism has not been fully elucidated yet. In this study, we report that the sodium arsenite-induced gene expression of the small heterodimer partner (SHP; NR0B2), an atypical orphan nuclear receptor, regulates the expression of hepatic gluconeogenic genes. Sodium arsenite augments hepatic SHP mRNA levels in an AMP-activated protein kinase (AMPK)-dependent manner. Sodium arsenite activated AMPK and was shown to perturb cellular ATP levels. The arsenite-induced SHP mRNA level was blocked by adenoviral overexpression of dominant negative AMPK (Ad-dnAMPKalpha) or by the AMPK inhibitor compound C in hepatic cell lines. We demonstrated the dose-dependent induction of SHP mRNA levels by sodium arsenite and repressed the forskolin/dexamethasone-induced gene expression of the key hepatic gluconeogenic genes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). Ad-dnAMPKalpha blocked the repressive effects of arsenite-induced SHP on PEPCK and G6Pase. Sodium arsenite inhibited the promoter activity of PEPCK and G6Pase, and this repression was abolished by small interfering (si)RNA SHP treatments. The knockdown of SHP expression by oligonucleotide siRNA SHP or adenoviral siRNA SHP released the sodium arsenite-mediated repression of forskolin/dexamethasone-stimulated PEPCK and G6Pase gene expression in a variety of hepatic cell lines. Results from our study suggest that sodium arsenite induces SHP via AMPK to inhibit the expression of hepatic gluconeogenic genes and also provide us with a novel molecular mechanism of arsenite-mediated regulation of hepatic glucose homeostasis.     

The role of hepatic, renal and intestinal gluconeogenic enzymes in glucose homeostasis of juvenile rainbow trout

Rainbow trout is unable to utilize high levels of dietary carbohydrates and experiences hyperglycemia after consumption of carbohydrate-rich meals. Carbohydrates stimulate hepatic glycolytic activity, but gene expression of the rate-limiting gluconeogenic enzymes glucose-6-phosphatase (G6Pase), fructose-1,6-bisphosphatase (FBPase) and phosphoenolpyruvate carboxykinase (PEPCK) remains high. Although there is significant mRNA expression and activity of gluconeogenic enzymes in trout intestine and kidney, the regulation of these enzymes by diet is not known. We tested the hypothesis that dietary carbohydrate modulates intestinal and renal G6Pase, FBPase and PEPCK. Fish were either fasted or fed isocaloric carbohydrate-free (CF) or high carbohydrate (HC) diets for 14 days. As expected, fish fed HC exhibited postprandial hyperglycemia and enhanced levels of hepatic glucokinase mRNA and activity. Dietary carbohydrates had no significant effect on the expression and activity of PEPCK, FBPase and G6Pase in all three organs. In contrast, fasting enhanced the activity, but not the mRNA expression of both hepatic and intestinal PEPCK, as well as intestinal FBPase. Therefore, the activity of rate-limiting gluconeogenic enzymes in trout can be modified by fasting, but not by the carbohydrate content of the diet, potentially causing hyperglycemia when fed high levels of dietary carbohydrates. In this species consuming low carbohydrate diets at infrequent intervals in the wild, fasting-induced increases in hepatic and intestinal gluconeogenic enzyme activities may be a key adaptation to prevent perturbations in blood glucose during food deprivation. Presented in part at Experimental Biology, April 2006, San Francisco, CA [Kirchner S., Panserat S., Kaushik S. and Ferraris R. FASEB-IUPS-2006 A667.6].     

Signal-dependent control of gluconeogenic key enzyme genes through coactivator-associated arginine methyltransferase 1

Together with impaired glucose uptake in skeletal muscle, elevated hepatic gluconeogenesis is largely responsible for the hyperglycemic phenotype in type II diabetic patients. Intracellular glucocorticoid and cyclic adenosine monophosphate (cAMP)/protein kinase A-dependent signaling pathways contribute to aberrant hepatic glucose production through the induction of gluconeogenic enzyme gene expression. Here we show that the coactivator-associated arginine methyltransferase 1 (CARM1) is required for cAMP-mediated activation of rate-limiting gluconeogenic phosphoenolpyruvate carboxykinase (PEPCK; EC 4.1.1.32) and glucose-6-phosphatase genes. Mutational analysis showed that CARM1 mediates its effect via the cAMP-responsive element within the PEPCK promoter, which is identified here as a CARM1 target in vivo. In hepatocytes, endogenous CARM1 physically interacts with cAMP-responsive element binding factor CREB and is recruited to the PEPCK and glucose-6-phosphatase promoters in a cAMP-dependent manner associated with increased promoter methylation. CARM1 might, therefore, represent a critical component of cAMP-dependent glucose metabolism in the liver.     

Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice

The ability of insulin to suppress gluconeogenesis in type II diabetes mellitus is impaired; however, the cellular mechanisms for this insulin resistance remain poorly understood. To address this question, we generated transgenic (TG) mice overexpressing the phosphoenolpyruvate carboxykinase (PEPCK) gene under control of its own promoter. TG mice had increased basal hepatic glucose production (HGP), but normal levels of plasma free fatty acids (FFAs) and whole-body glucose disposal during a hyperinsulinemic-euglycemic clamp compared with wild-type controls. The steady-state levels of PEPCK and glucose-6-phosphatase mRNAs were elevated in livers of TG mice and were resistant to down-regulation by insulin. Conversely, GLUT2 and glucokinase mRNA levels were appropriately regulated by insulin, suggesting that insulin resistance is selective to gluconeogenic gene expression. Insulin-stimulated phosphorylation of the insulin receptor, insulin receptor substrate (IRS)-1, and associated phosphatidylinositol 3-kinase were normal in TG mice, whereas IRS-2 protein and phosphorylation were down-regulated compared with control mice. These results establish that a modest (2-fold) increase in PEPCK gene expression in vivo is sufficient to increase HGP without affecting FFA concentrations. Furthermore, these results demonstrate that PEPCK overexpression results in a metabolic pattern that increases glucose-6-phosphatase mRNA and results in a selective decrease in IRS-2 protein, decreased phosphatidylinositol 3-kinase activity, and reduced ability of insulin to suppress gluconeogenic gene expression. However, acute suppression of HGP and glycolytic gene expression remained intact, suggesting that FFA and/or IRS-1 signaling, in addition to reduced IRS-2, plays an important role in downstream insulin signal transduction pathways involved in control of gluconeogenesis and progression to type II diabetes mellitus.     

A modest glucokinase overexpression in the liver promotes fed expression levels of glycolytic and lipogenic enzyme genes in the fasted state without altering SREBP-1c expression

Hepatic genes crucial for carbohydrate and lipid homeostasis are regulated by insulin and glucose metabolism. However, the relative contributions of insulin and glucose to the regulation of metabolic gene expression are poorly defined in vivo. To address this issue, adenovirus-mediated hepatic overexpression of glucokinase was used to determine the effects of increased hepatic glucose metabolism on gene expression in fasted or ad libitum fed rats. In the fasted state, a 3 fold glucokinase overexpression was sufficient to mimic feeding-induced increases in pyruvate kinase and acetyl CoA carboxylase mRNA levels, demonstrating a primary role for glucose metabolism in the regulation of these genes in vivo. Conversely, glucokinase overexpression was unable to mimic feeding-induced alterations of fatty acid synthase, glucose-6-phosphate dehydrogenase, carnitine palmitoyl transferase I or PEPCK mRNAs, indicating insulin as the primary regulator of these genes. Interestingly, glucose-6-phosphatase mRNA was increased by glucokinase overexpression in both the fasted and fed states, providing evidence, under these conditions, for the dominance of glucose over insulin signaling for this gene in vivo. Importantly, glucokinase overexpression did not alter sterol regulatory element binding protein 1-c mRNA levels in vivo and glucose signaling did not alter the expression of this gene in primary hepatocytes. We conclude that a modest hepatic overexpression of glucokinase is sufficient to alter expression of metabolic genes without changing the expression of SREBP-1c.